LLY

1,076.26

+0.08%↑

JNJ

206.89

+0.14%↑

ABBV

229.02

+0.55%↑

UNH

328.59

-0.44%↓

AZN

92.61

-0.13%↓

LLY

1,076.26

+0.08%↑

JNJ

206.89

+0.14%↑

ABBV

229.02

+0.55%↑

UNH

328.59

-0.44%↓

AZN

92.61

-0.13%↓

LLY

1,076.26

+0.08%↑

JNJ

206.89

+0.14%↑

ABBV

229.02

+0.55%↑

UNH

328.59

-0.44%↓

AZN

92.61

-0.13%↓

LLY

1,076.26

+0.08%↑

JNJ

206.89

+0.14%↑

ABBV

229.02

+0.55%↑

UNH

328.59

-0.44%↓

AZN

92.61

-0.13%↓

LLY

1,076.26

+0.08%↑

JNJ

206.89

+0.14%↑

ABBV

229.02

+0.55%↑

UNH

328.59

-0.44%↓

AZN

92.61

-0.13%↓

Начало・Списък с акции・BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc

Отворен

СекторЗдравеопазване

7.04 -1.95

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

7.01

Максимум

7.18

Ключови измерители
By Trading Economics
Приходи	7.8M 13M
Продажби	-4M 159M
Марж на печалбата	8.092
Служители	580
EBITDA	3.7M 32M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+168.38% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-101M 1.4B
Предишно отваряне	8.99
Предишно затваряне	7.04

Настроения в новините

By Acuity

67%

33%

330 / 374 Класиране в Healthcare

BioCryst Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

28.11.2025 г., 15:29 ч. UTC

Значими двигатели на пазара

Придобивния, сливания и поглъщания

China's Jiangxi Copper Rejected by SolGold in $1 Billion Takeover Approach

30.11.2025 г., 23:50 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

30.11.2025 г., 23:50 ч. UTC

Пазарно говорене

Nikkei May Decline Amid Uncertainty Over U.S. Economy, Japan Earnings -- Market Talk

30.11.2025 г., 22:24 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

30.11.2025 г., 22:24 ч. UTC

Пазарно говорене

Australian Equities Typically Rise in Year Before Rate Hikes Start -- Market Talk

30.11.2025 г., 07:30 ч. UTC

Придобивния, сливания и поглъщания

Strategy Insiders Kept Buying Preferred Stock as Bitcoin Price Slid -- Barrons.com

28.11.2025 г., 21:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

28.11.2025 г., 19:59 ч. UTC

Пазарно говорене

Oil Futures Settle Lower in Slow Black Friday Trade -- Market Talk

28.11.2025 г., 19:47 ч. UTC

Пазарно говорене

U.S. Natural Gas Lifted By Cold Weather Outlook -- Market Talk

28.11.2025 г., 18:16 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

28.11.2025 г., 18:16 ч. UTC

Пазарно говорене

Messy Canada GDP Data Still Seen as Cause for Optimism in 2026 -- Market Talk

28.11.2025 г., 18:08 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

28.11.2025 г., 18:08 ч. UTC

Пазарно говорене

Messy Canada GDP Data Still Seen as Cause for Optimism in 2026 -- Market Talk

28.11.2025 г., 17:48 ч. UTC

Пазарно говорене

Bank of Canada May Revise Up Inflation Projections After GDP Data -- Market Talk

28.11.2025 г., 17:20 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

28.11.2025 г., 16:50 ч. UTC

Придобивния, сливания и поглъщания

Week's Best: Sieg's Stature at Citi Grows -- Barrons.com

28.11.2025 г., 15:51 ч. UTC

Пазарно говорене

Canada Household Spending Edges Lower -- Market Talk

28.11.2025 г., 15:33 ч. UTC

Пазарно говорене

Crude Futures Gain as U.S. Market Reopens -- Market Talk

28.11.2025 г., 15:21 ч. UTC

Пазарно говорене

Gold Rises on U.S. Rate-Cut Bets After CME Outage -- Market Talk

28.11.2025 г., 15:13 ч. UTC

Пазарно говорене

Dollar Recovers Slightly as Investors Already Price in Fed Rate Cut -- Market Talk

28.11.2025 г., 15:11 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

28.11.2025 г., 15:11 ч. UTC

Пазарно говорене

Canadian National Railway Showing Positive Trend Going Into 2026 -- Market Talk

28.11.2025 г., 14:51 ч. UTC

Пазарно говорене

Canada GDP Report Masks Fragile State of Economy -- Market Talk

28.11.2025 г., 14:41 ч. UTC

Пазарно говорене

Canada's GDP Level Pulled Higher by 'Eye-Opening' Revisions -- Market Talk

28.11.2025 г., 14:37 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Rise As Temperatures Drop -- Market Talk

28.11.2025 г., 14:33 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

28.11.2025 г., 14:33 ч. UTC

Пазарно говорене

Steep Import Drop Fuels Surprise Lift in Canada GDP -- Market Talk

28.11.2025 г., 14:20 ч. UTC

Пазарно говорене

Too Much Noise in Canada's Surprise 3Q GDP Gain -- Market Talk

28.11.2025 г., 14:10 ч. UTC

Пазарно говорене

Canadian Nowcast Came Closest to Predicting Surprise 3Q Strength -- Market Talk

28.11.2025 г., 13:39 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

BioCryst Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

168.38% нагоре

12-месечна прогноза

Среден 19.27 USD 168.38%

Висок 30 USD

Нисък 8 USD

Според 11 анализатори от Wall Street, предложили 12-месечна ценова цел за BioCryst Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

11 ratings

Купи

Задържане

Продай

Според 11 анализатори, дали борсови рейтинги на BioCryst Pharmaceuticals Inc през последните 3 месеца.

Настроение

By Acuity

330 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.